<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Zai Lab Ltd. — News on 6ix</title>
    <link>https://6ix.com/company/zai-lab-ltd</link>
    <description>Latest news and press releases for Zai Lab Ltd. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 11 May 2026 11:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/zai-lab-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836902f78dffbe2df16e74b.webp</url>
      <title>Zai Lab Ltd.</title>
      <link>https://6ix.com/company/zai-lab-ltd</link>
    </image>
    <item>
      <title>Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)</title>
      <link>https://6ix.com/company/zai-lab-ltd/news/zai-lab-receives-us-fda-fast-track-designation-for-zocilurtatug-pelitecan-zoci-a-dll3-targeting-adc-for-treatment-of-extrapulmonary-neuroendocrine-carcinomas-epnecs</link>
      <guid isPermaLink="true">https://6ix.com/company/zai-lab-ltd/news/zai-lab-receives-us-fda-fast-track-designation-for-zocilurtatug-pelitecan-zoci-a-dll3-targeting-adc-for-treatment-of-extrapulmonary-neuroendocrine-carcinomas-epnecs</guid>
      <pubDate>Mon, 11 May 2026 11:00:00 GMT</pubDate>
      <description>SHANGHAI &amp; CAMBRIDGE, Mass., May 11, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company’s potential first-in-class Delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), for the treatment of extrapulmonary neuroendocrine carcinomas (epNECs) following progression after standard first-line therapy. epNECs are an aggressive maligna</description>
    </item>
    <item>
      <title>Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates</title>
      <link>https://6ix.com/company/zai-lab-ltd/news/zai-lab-announces-first-quarter-2026-financial-results-and-recent-corporate-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/zai-lab-ltd/news/zai-lab-announces-first-quarter-2026-financial-results-and-recent-corporate-updates</guid>
      <pubDate>Thu, 07 May 2026 10:00:00 GMT</pubDate>
      <description>SHANGHAI &amp; CAMBRIDGE, Mass., May 07, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2026, along with recent product highlights and corporate updates.</description>
    </item>
    <item>
      <title>Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026</title>
      <link>https://6ix.com/company/zai-lab-ltd/news/zai-lab-to-announce-first-quarter-2026-financial-results-and-recent-corporate-updates-on-may-7-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/zai-lab-ltd/news/zai-lab-to-announce-first-quarter-2026-financial-results-and-recent-corporate-updates-on-may-7-2026</guid>
      <pubDate>Wed, 22 Apr 2026 11:30:00 GMT</pubDate>
      <description>SHANGHAI &amp; CAMBRIDGE, Mass., April 22, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its first quarter 2026 financial results and provide recent corporate updates on May 7, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT).</description>
    </item>
    <item>
      <title>Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases</title>
      <link>https://6ix.com/company/zai-lab-ltd/news/zai-lab-presents-new-preclinical-data-suggesting-zl-1503-an-il-13il-31ra-bispecific-antibody-provides-rapid-itch-relief-and-reduction-in-inflammation-in-atopic-diseases</link>
      <guid isPermaLink="true">https://6ix.com/company/zai-lab-ltd/news/zai-lab-presents-new-preclinical-data-suggesting-zl-1503-an-il-13il-31ra-bispecific-antibody-provides-rapid-itch-relief-and-reduction-in-inflammation-in-atopic-diseases</guid>
      <pubDate>Sat, 18 Apr 2026 13:00:00 GMT</pubDate>
      <description>SHANGHAI &amp; CAMBRIDGE, Mass., April 18, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced new data from a preclinical study of ZL-1503, demonstrating that the company’s internally developed IL-13/IL-31Rα bispecific antibody may lead to sustained suppression of intense pruritus (itch) and inflammation caused by atopic diseases. The findings, featured in a poster presentation at the IMMUNOLOGY2026 conference in Boston, MA, reinforce the potential of ZL-1503 to be a first-in-class tre</description>
    </item>
    <item>
      <title>Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas</title>
      <link>https://6ix.com/company/zai-lab-ltd/news/zai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan-zoci-induces-rapid-and-robust-intracranial-responses-in-small-cell-lung-cancer-with-brain-metastases-and-promising-activity-in-other-neuroendocrine-carcinomas</link>
      <guid isPermaLink="true">https://6ix.com/company/zai-lab-ltd/news/zai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan-zoci-induces-rapid-and-robust-intracranial-responses-in-small-cell-lung-cancer-with-brain-metastases-and-promising-activity-in-other-neuroendocrine-carcinomas</guid>
      <pubDate>Fri, 17 Apr 2026 19:01:00 GMT</pubDate>
      <description>SHANGHAI &amp; CAMBRIDGE, Mass., April 17, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced clinical data indicating zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), provides rapid and robust intracranial responses in patients with previously treated extensive stage small cell lung cancer (ES-SCLC) and brain metastases as measured by independent assessment using modified Response Assessment in Neuro-Oncology for Brain Metastases (mRANO-</description>
    </item>
    <item>
      <title>Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas</title>
      <link>https://6ix.com/company/zai-lab-ltd/news/boehringer-ingelheim-and-zai-lab-announce-collaboration-on-dll3targeting-tcell-engager-and-adc-combination-in-small-cell-lung-cancer-and-other-neuroendocrine-carcinomas</link>
      <guid isPermaLink="true">https://6ix.com/company/zai-lab-ltd/news/boehringer-ingelheim-and-zai-lab-announce-collaboration-on-dll3targeting-tcell-engager-and-adc-combination-in-small-cell-lung-cancer-and-other-neuroendocrine-carcinomas</guid>
      <pubDate>Wed, 15 Apr 2026 12:00:00 GMT</pubDate>
      <description>Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs). Phase Ib/II study will test the combination of obrixtamig, a DLL3/CD3 T‑cell engager, with Zai Lab’s zocilurtatug pelitecan (zoci), a DLL3‑targeting antibody–drug conjugate (ADC), to explore safety and potential increase in clinical benefit for patients. Ingelheim, Germany and Shanghai, China/Cambridge,</description>
    </item>
    <item>
      <title>Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy</title>
      <link>https://6ix.com/company/zai-lab-ltd/news/zai-lab-announces-global-clinical-trial-collaboration-and-supply-agreement-to-evaluate-novel-dll3-adc-zocilurtatug-pelitecan-in-combination-with-a-bispecific-t-cell-engager-therapy-1</link>
      <guid isPermaLink="true">https://6ix.com/company/zai-lab-ltd/news/zai-lab-announces-global-clinical-trial-collaboration-and-supply-agreement-to-evaluate-novel-dll3-adc-zocilurtatug-pelitecan-in-combination-with-a-bispecific-t-cell-engager-therapy-1</guid>
      <pubDate>Wed, 01 Apr 2026 11:30:00 GMT</pubDate>
      <description>SHANGHAI &amp; CAMBRIDGE, Mass., April 01, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a global clinical trial collaboration with Amgen Inc. (NASDAQ: AMGN) to evaluate Zai Lab’s investigational delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci, formerly ZL-1310), in combination with Amgen’s IMDELLTRA® (tarlatamab-dlle), a DLL3-targeting Bispecific T-cell Engager (BiTE®) therapy in patients with extensive-stage small cell lung cancer</description>
    </item>
    <item>
      <title>Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)</title>
      <link>https://6ix.com/company/zai-lab-ltd/news/zai-lab-to-present-new-data-on-three-internally-developed-oncology-candidates-at-aacr-2026-including-zocilurtatug-pelitecan-a-dll3-targeting-antibody-drug-conjugate-adc</link>
      <guid isPermaLink="true">https://6ix.com/company/zai-lab-ltd/news/zai-lab-to-present-new-data-on-three-internally-developed-oncology-candidates-at-aacr-2026-including-zocilurtatug-pelitecan-a-dll3-targeting-antibody-drug-conjugate-adc</guid>
      <pubDate>Tue, 17 Mar 2026 20:35:00 GMT</pubDate>
      <description>SHANGHAI &amp; CAMBRIDGE, Mass., March 17, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced three of the Company’s internally-developed investigational oncology therapies will be presented across four poster sessions at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17-22 in San Diego, California. These next-generation candidates include: zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC</description>
    </item>
    <item>
      <title>Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates</title>
      <link>https://6ix.com/company/zai-lab-ltd/news/zai-lab-announces-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/zai-lab-ltd/news/zai-lab-announces-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-updates</guid>
      <pubDate>Thu, 26 Feb 2026 12:00:00 GMT</pubDate>
      <description>SHANGHAI &amp; CAMBRIDGE, Mass., February 26, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2025, along with recent product highlights and corporate updates.</description>
    </item>
    <item>
      <title>Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026</title>
      <link>https://6ix.com/company/zai-lab-ltd/news/zai-lab-announce-fourth-quarter-133000041</link>
      <guid isPermaLink="true">https://6ix.com/company/zai-lab-ltd/news/zai-lab-announce-fourth-quarter-133000041</guid>
      <pubDate>Tue, 10 Feb 2026 13:30:00 GMT</pubDate>
      <description>SHANGHAI &amp; CAMBRIDGE, Mass., February 10, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its fourth quarter and full year 2025 financial results and provide recent corporate updates on February 26, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT).</description>
    </item>
    <item>
      <title>Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/zai-lab-ltd/news/zai-lab-highlights-strategic-priorities-and-global-pipeline-progress-at-44th-annual-jp-morgan-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/zai-lab-ltd/news/zai-lab-highlights-strategic-priorities-and-global-pipeline-progress-at-44th-annual-jp-morgan-healthcare-conference</guid>
      <pubDate>Tue, 13 Jan 2026 13:00:00 GMT</pubDate>
      <description>SHANGHAI &amp; CAMBRIDGE, Mass., January 13, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today provided an update on the Company’s 2026 strategic priorities and clinical development progress. These updates will be discussed as part of the Company’s presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET.</description>
    </item>
    <item>
      <title>Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors</title>
      <link>https://6ix.com/company/zai-lab-ltd/news/zai-lab-announces-national-medical-123000326</link>
      <guid isPermaLink="true">https://6ix.com/company/zai-lab-ltd/news/zai-lab-announces-national-medical-123000326</guid>
      <pubDate>Tue, 06 Jan 2026 12:30:00 GMT</pubDate>
      <description>SHANGHAI &amp; CAMBRIDGE, Mass., January 06, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products...</description>
    </item>
    <item>
      <title>Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/zai-lab-ltd/news/zai-lab-to-present-at-44th-annual-jp-morgan-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/zai-lab-ltd/news/zai-lab-to-present-at-44th-annual-jp-morgan-healthcare-conference</guid>
      <pubDate>Mon, 05 Jan 2026 12:30:00 GMT</pubDate>
      <description>SHANGHAI &amp; CAMBRIDGE, Mass., January 05, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13th, 2026, at 3:00 p.m. PST / 6:00 p.m. EST.</description>
    </item>
    <item>
      <title>Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia</title>
      <link>https://6ix.com/company/zai-lab-ltd/news/zai-lab-announces-approval-of-cobenfy-xanomeline-and-trospium-chloride-in-china-a-first-in-class-therapy-for-schizophrenia</link>
      <guid isPermaLink="true">https://6ix.com/company/zai-lab-ltd/news/zai-lab-announces-approval-of-cobenfy-xanomeline-and-trospium-chloride-in-china-a-first-in-class-therapy-for-schizophrenia</guid>
      <pubDate>Tue, 23 Dec 2025 12:30:00 GMT</pubDate>
      <description>SHANGHAI &amp; CAMBRIDGE, Mass., December 23, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) approved the New Drug Application (NDA) for COBENFY® (xanomeline and trospium chloride) for the treatment of schizophrenia in adults. COBENFY is the first schizophrenia therapy with a novel mechanism of action approved in over 70 years [1], offering a fundamentally new approach to treating schizophrenia. By selectively activating</description>
    </item>
    <item>
      <title>Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis</title>
      <link>https://6ix.com/company/zai-lab-ltd/news/zai-lab-announces-dosing-of-first-participant-in-global-phase-11b-study-of-zl-1503-an-il-13il-31r-bispecific-antibody-for-the-treatment-of-atopic-dermatitis</link>
      <guid isPermaLink="true">https://6ix.com/company/zai-lab-ltd/news/zai-lab-announces-dosing-of-first-participant-in-global-phase-11b-study-of-zl-1503-an-il-13il-31r-bispecific-antibody-for-the-treatment-of-atopic-dermatitis</guid>
      <pubDate>Mon, 08 Dec 2025 12:00:00 GMT</pubDate>
      <description>SHANGHAI &amp; CAMBRIDGE, Mass., December 08, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the dosing of the first participant in a global Phase 1/1b clinical trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of ZL-1503, a potential first-in-class IL-13/IL-31R bispecific antibody for the treatment of atopic dermatitis (AD). ZL-1503, which was identified and advanced internally by Zai Lab’s discovery team, targets both IL-13 and IL-31 pathways with an exten</description>
    </item>
    <item>
      <title>Zai Lab Announces Updates to China’s National Reimbursement Drug List</title>
      <link>https://6ix.com/company/zai-lab-ltd/news/zai-lab-announces-updates-to-chinas-national-reimbursement-drug-list</link>
      <guid isPermaLink="true">https://6ix.com/company/zai-lab-ltd/news/zai-lab-announces-updates-to-chinas-national-reimbursement-drug-list</guid>
      <pubDate>Sun, 07 Dec 2025 05:11:00 GMT</pubDate>
      <description>SHANGHAI &amp; CAMBRIDGE, Mass., December 07, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the following medicines and indications have been renewed in the 2025 National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA):</description>
    </item>
    <item>
      <title>Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates</title>
      <link>https://6ix.com/company/zai-lab-ltd/news/zai-lab-announces-third-quarter-2025-financial-results-and-recent-corporate-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/zai-lab-ltd/news/zai-lab-announces-third-quarter-2025-financial-results-and-recent-corporate-updates</guid>
      <pubDate>Thu, 06 Nov 2025 12:00:00 GMT</pubDate>
      <description>SHANGHAI &amp; CAMBRIDGE, Mass., November 06, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2025, along with recent product highlights and corporate updates.</description>
    </item>
    <item>
      <title>Zai Lab Announces Participation in Investor Conferences in November and December 2025</title>
      <link>https://6ix.com/company/zai-lab-ltd/news/zai-lab-announces-participation-in-investor-conferences-in-november-and-december-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/zai-lab-ltd/news/zai-lab-announces-participation-in-investor-conferences-in-november-and-december-2025</guid>
      <pubDate>Fri, 31 Oct 2025 11:30:00 GMT</pubDate>
      <description>SHANGHAI &amp; CAMBRIDGE, Mass., October 31, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November and December 2025:</description>
    </item>
    <item>
      <title>Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study</title>
      <link>https://6ix.com/company/zai-lab-ltd/news/zai-lab-announces-updated-phase-1-data-for-zocilurtatug-pelitecan-formerly-zl-1310-demonstrating-potential-as-a-first-in-classbest-in-class-dll3-targeted-adc-for-small-cell-lung-cancer-and-initiation-of-global-phase-3-registrational-study</link>
      <guid isPermaLink="true">https://6ix.com/company/zai-lab-ltd/news/zai-lab-announces-updated-phase-1-data-for-zocilurtatug-pelitecan-formerly-zl-1310-demonstrating-potential-as-a-first-in-classbest-in-class-dll3-targeted-adc-for-small-cell-lung-cancer-and-initiation-of-global-phase-3-registrational-study</guid>
      <pubDate>Fri, 24 Oct 2025 13:00:00 GMT</pubDate>
      <description>SHANGHAI &amp; CAMBRIDGE, Mass., October 24, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced updated data from the global Phase 1 clinical trial of zocilurtatug pelitecan (zoci), formerly known as ZL-1310, (NCT06179069) demonstrating robust and durable responses in heavily pre-treated patients with extensive-stage small cell lung cancer (ES-SCLC). This data will be presented as an oral presentation and was included as part of the press program at the AACR-NCI-EORTC International Con</description>
    </item>
    <item>
      <title>Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025</title>
      <link>https://6ix.com/company/zai-lab-ltd/news/zai-lab-to-announce-third-quarter-2025-financial-results-and-recent-corporate-updates-on-november-6-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/zai-lab-ltd/news/zai-lab-to-announce-third-quarter-2025-financial-results-and-recent-corporate-updates-on-november-6-2025</guid>
      <pubDate>Wed, 15 Oct 2025 11:30:00 GMT</pubDate>
      <description>SHANGHAI &amp; CAMBRIDGE, Mass., October 15, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its third quarter 2025 financial results and provide recent corporate updates on November 6, 2025, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT).</description>
    </item>
  </channel>
</rss>